Sonoma Pharmaceuticals (SNOA) AI Stock Analysis

• Market Cap: $4.51M
• Dividend Yield: N/A
• Average Volume (3M): 65.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.31
• Revenue Growth: 25.02%
• EPS Growth: 55.11%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.35
• Shares Outstanding: 1,730,613
• 10 Day Avg. Volume: 126,678
• 30 Day Avg. Volume: 65,281
• PEG Ratio: 0.02
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.19
• P/FCF Ratio: -16.18
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 0.12
• Enterprise Value/Gross Profit: 0.33
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.61
• Revenue Forecast (FY): $20.66M

• Rating: 44 Neutral
• Price Target: $2.50 ▼(-33.86% Downside)
• Action: Reiterated Date: 02/12/26
• Date: Action: Reiterated 02/12/26

The score is held down primarily by weak financial quality—ongoing losses, poor ROE, and continued negative operating/free cash flow—despite modest revenue growth and low leverage. Technicals add pressure due to a clear downtrend (below major moving averages with negative MACD), even though the stock is oversold. Corporate updates are constructive around portfolio and distribution momentum, but do not yet offset the current profitability and cash-burn profile; valuation is also constrained by losses (negative P/E) and no dividend support.

Positive Factors

Proprietary HOCl platform

Sonoma's patented HOCl technology and broad Microcyn product set create durable differentiation across dermatology, wound care, eye care and other large markets. Clinical backing, ongoing product innovation and expanding distributor relationships support sustained market penetration and higher switching costs.

Low financial leverage

Low debt levels reduce near-term refinancing and solvency risk, giving management flexibility to invest in commercialization and international expansion. This structural liquidity cushion matters over months while the company works to stabilize operations and reduce cash burn.

Stable gross margin and revenue resilience

Steady gross margins indicate cost-effective manufacturing and a defendable product economics base. Combined with modest top-line growth, this suggests core products can scale with distribution gains and support eventual leverage of operating expenses into improved profitability.

Negative Factors

Negative operating and free cash flow

Sustained negative operating and free cash flow means the business consumes cash and is not self-funding. Over a multi-month horizon this necessitates external financing or asset sales, which can dilute shareholders or increase leverage and constrain investment in growth initiatives.

Persistent net losses

Deep negative net margins show the company has not achieved operating break‑even. Until consistent positive EBITDA and net income are delivered, Sonoma will face recurring pressure on capital, limit reinvestment capacity, and need to prove durable margin improvements to sustain growth.

Very poor returns on equity

Severely negative returns on equity reflect ongoing value erosion and weaken the capital base. This structural deterioration reduces investor flexibility, raises the likelihood of strategic or financing actions, and undermines long-term capacity to fund R&D or commercial expansion organically.

Sonoma Pharmaceuticals Business Overview & Revenue Model

Company Description

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

How the Company Makes Money

Sonoma Pharmaceuticals generates revenue primarily through the sale of its therapeutic products, which include prescription and over-the-counter formulations. Key revenue streams are derived from direct product sales to healthcare providers, hospitals, and pharmacies, as well as partnerships with distributors and licensees in various global markets. The company also benefits from collaborations with research institutions and healthcare organizations to advance its product pipeline and expand its market reach. Additionally, Sonoma may receive royalties from licensing agreements related to its proprietary technologies and formulations, contributing to overall earnings.

Sonoma Pharmaceuticals Financial Statement Overview

Summary

Modest revenue growth (+4.6%) and stable gross margin (~37–38%) show some resilience, and leverage is low (debt-to-equity ~0.14). However, profitability remains weak (TTM net margin ~-21%), returns on equity are very poor (-65% to -81%), and cash flow is still meaningfully negative (TTM operating cash flow about -$2.8M; free cash flow about -$3.0M), indicating ongoing cash burn and financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is up (+4.6%) and gross margin is steady around ~37–38%, showing some top-line resilience. However, profitability remains weak: operating and net margins are still deeply negative (TTM net margin about -21%), and the company continues to post losses despite some improvement versus prior-year annual results. Overall, the income statement reflects modest stabilization but no clear break-even trajectory yet.

Balance Sheet

Leverage looks manageable with low debt relative to equity (TTM debt-to-equity ~0.14), which reduces near-term balance sheet stress. The key weakness is persistent value erosion from losses, reflected in very poor returns on equity (roughly -65% to -81% across periods) and a multi-year decline in equity from earlier annual reports. In short: low financial leverage, but ongoing losses are pressuring the capital base.

Cash Flow

Cash generation remains a major issue. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$2.8M and -$3.0M), indicating the business is still consuming cash. While free cash flow has improved sharply versus the prior annual period (growth rate shown as strongly positive), cash flow is not yet self-funding and remains dependent on external liquidity over time.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	17.72M	14.29M	12.73M	13.27M	12.63M	18.63M
Gross Profit	6.76M	5.46M	4.75M	4.48M	3.99M	6.56M
EBITDA	-3.02M	-3.57M	-4.53M	-4.45M	-5.70M	-3.22M
Net Income	-3.37M	-3.46M	-4.83M	-5.15M	-5.09M	-3.95M
Balance Sheet
Total Assets	13.62M	13.69M	14.74M	16.23M	18.84M	14.99M
Cash, Cash Equivalents and Short-Term Investments	2.56M	5.37M	3.13M	3.82M	7.40M	4.22M
Total Debt	655.00K	305.00K	608.00K	849.00K	1.37M	2.67M
Total Liabilities	10.19M	9.28M	8.60M	8.25M	10.15M	9.62M
Stockholders Equity	3.43M	4.41M	6.14M	7.98M	8.70M	5.36M
Cash Flow
Free Cash Flow	-2.51M	-168.00K	-2.42M	-6.42M	-4.38M	-3.56M
Operating Cash Flow	-2.31M	-88.00K	-2.40M	-6.15M	-4.25M	-3.38M
Investing Cash Flow	-202.00K	-80.00K	-2.00K	-258.00K	-99.00K	388.00K
Financing Cash Flow	1.10M	3.03M	1.68M	2.49M	7.40M	3.31M

Sonoma Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Negative. The current price of 3.78 is above the 20-day moving average (MA) of 2.81, above the 50-day MA of 3.20, and above the 200-day MA of 3.57, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 23.69 is Positive, neither overbought nor oversold. The STOCH value of 24.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNOA.

Sonoma Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RDHL	47 Neutral	$4.81M	-0.42	―	―	―	―
SNOA	44 Neutral	$4.51M	-1.90	-76.14%	―	25.02%	55.11%
SBFM	44 Neutral	$5.59M	-1.96	-24.34%	―	13.24%	98.80%
CPHI	42 Neutral	$2.97M	-2.90	-42.47%	―	-26.92%	69.90%
SHPH	32 Underperform	$2.83M	-0.84	-9999.00%	―	―	79.31%

Sonoma Pharmaceuticals Corporate Events

Sonoma Pharmaceuticals Updates Investor Presentation on HOCl Portfolio

In January 2026, Sonoma Pharmaceuticals released an updated investor presentation highlighting its leadership in hypochlorous acid technology and the breadth of its Microcyn product portfolio across billion‑dollar markets such as prescription and over‑the‑counter dermatology, wound care, eye care, podiatry, animal health and non‑toxic disinfectants. The company detailed its strong safety and efficacy profile, extensive clinical and research backing, diversified global distribution footprint and cost‑efficient manufacturing, while also underscoring recent commercial momentum, including the addition of Medline Industries as a U.S. wound care distributor in August 2024, expansion of that partnership to Canada and OTC channels in October 2024, new wound care distribution in Ukraine, and ongoing product innovation such as expanded negative pressure wound therapy solutions and an intraoperative pulse lavage irrigation application announced in June 2023, developments that collectively aim to accelerate international growth and deepen market penetration for its HOCl‑based technologies.

The most recent analyst rating on (SNOA) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Sonoma Pharmaceuticals stock, see the SNOA Stock Forecast page.